Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 0.3% – Here’s What Happened

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s stock price dropped 0.3% during trading on Tuesday . The stock traded as low as $1.44 and last traded at $1.48. Approximately 34,880 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 40,838 shares. The stock had previously closed at $1.4850.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Cyclerion Therapeutics Price Performance

The company has a market capitalization of $5.82 million, a P/E ratio of -1.97 and a beta of 0.94. The company has a 50 day moving average of $1.39 and a 200-day moving average of $1.74.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. 75.62% of the stock is owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.